Adaptimmune Therapeutics (ADAP) TD Cowen 45th Annual Healthcare Conference summary

Company and product overview

• Focuses on engineered cell therapies for solid tumors, with a proprietary platform and pipeline.

• Achieved first approval for an engineered T-cell therapy in solid tumors with Tecelra for advanced synovial sarcoma.

• Lete-cel, targeting NY-ESO-1, is about two years behind Tecelra and addresses additional sarcoma populations.

• Pipeline includes PRAME and MAGE-A10 (in partnership with Galapagos) and preclinical CD70 programs.

• Emphasizes integrated manufacturing and commercial operations to support product delivery.

Market opportunity and commercial strategy

• Tecelra targets about 400 eligible U.S. patients annually; lete-cel expands the addressable population to over 1,000.

• Both products leverage nearly 100% commercial synergy, minimizing incremental costs.

• Peak sarcoma franchise sales guidance is $400 million, assuming high penetration due to lack of alternatives.

• Commercial organization becomes self-sustaining at 70–90 treated patients per year, with Tecelra priced at GBP 727,000 and ~70% margin.

• Uptake has been strong, with 13 treatment centers activated and plans to reach 30 by year-end.

Launch experience and payer dynamics

• Early launch has met expectations, with rapid treatment center activation and strong physician demand.

• First patient dosed within four months of launch; initial revenues in Q4, with acceleration expected in 2025.

• Over 70% of commercial and Medicare lives are covered by plans with Tecelra policies.

• Centralized and sponsored biomarker testing is in place, with expansion plans to standard diagnostic panels.